LARTRUVO

This brand name is authorized in Brazil, Estonia, Ireland, Lithuania, Poland, United States

Active ingredients

The drug LARTRUVO contains one active pharmaceutical ingredient (API):

1 Olaratumab UNII TT6HN20MVF - OLARATUMAB

Olaratumab is an antagonist of platelet derived growth factor receptor-α (PDGFR-α), expressed on tumour and stromal cells. Olaratumab is a targeted, recombinant, fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that specifically binds PDGFR-α, blocking PDGF AA, -BB, and CC binding and receptor activation. As a result, in vitro olaratumab inhibits PDGFRα pathway signalling in tumour and stromal cells. In addition, in vivo olaratumab has been shown to disrupt the PDGFR-α pathway in tumour cells and inhibit tumour growth. Read about Olaratumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LARTRUVO Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX10	Olaratumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 507618030021401
Country: EE	Ravimiamet	Identifier(s): 1732766, 1753668, 1753679
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1081608, 1084355, 1084356
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100381944
Country: US	FDA, National Drug Code	Identifier(s): 0002-7190, 0002-8926